Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  GeNeuro    GNRO   CH0308403085

GENEURO (GNRO)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
04/19/2018 04/20/2018 04/23/2018 04/24/2018 04/25/2018 Date
6.36(c) 6.36(c) 6.2(c) 6.2(c) 6.2 Last
201 385 3 551 182 834 Volume
+0.32% 0.00% -2.52% 0.00% 0.00% Change
More quotes
Financials (EUR)
Sales 2017 5,20 M
EBIT 2017 -11,9 M
Net income 2017 -14,2 M
Finance 2017 22,9 M
Yield 2017 -
Sales 2018 12,6 M
EBIT 2018 -9,40 M
Net income 2018 -4,83 M
Finance 2018 5,90 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 13,4x
EV / Sales2018 6,88x
Capitalization 92,6 M
More Financials
Company
GeNeuro SA engages develops therapeutic products for disorders of the nervous system.It operates in the Research and Development segment for pharmaceutical products.The firm offers GNbAC1, a therapeutic antibody that targets MSRV-Env.It also offers a drug for multiple sclerosis.The company was... 
More about the company
Surperformance© ratings of GeNeuro
Trading Rating : Investor Rating :
More Ratings
Latest news on GENEURO
03/29GENEURO SA : annual earnings release
03/29GENEURO : and Servier announce successful 12-month results in neuroprotection fo..
AQ
02/24GENEURO : Receives Orphan Drug Designation from the US FDA for GNbAC1 in Chronic..
AQ
2017GENEURO : reports cash and revenue for Q3 2017
PU
2017GENEURO : Servier and GeNeuro Announce Promising post hoc Analyses of Six Month ..
AQ
2017GENEURO : Servier and Geneuro to present six month results from CHANGE-MS phase ..
AQ
2017GENEURO : Researchers from GeNeuro Describe Findings in Type 1 Diabetes Mellitus..
AQ
2017GENEURO : Retroviral RRMS Treatment GNbAC1 Fails Phase 2 Trial, But Research Con..
AQ
2017GENEURO : Servier and GeNeuro Announce Six-Month Results from CHANGE-MS Phase 2b..
AQ
2017GENEURO : updates on cash, revenue and activities at Q2 2017
PU
More news
Sector news : Biotechnology & Medical Research - NEC
03:11pCurrency and pricing squeeze GSK as new shingles vaccine shines
RE
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
03/26$TSPT : GeNeuro Hits on 12-Month Data Readout; Clear Signs of Neuroprotective.. 
03/23$TSPT https://t.co/1330rfZH3Y: Pay Attention to GeNeuro; Final Phase IIb Resu.. 
02/22GeNeuro : Receives Orphan Drug Designation from the US FDA for GNbAC1 in Chro.. 
02/12GeNeuro : Reports Cash and Revenue at December 31, 2017  
01/10$TSPT GNRO.PA: GeNeuro Enrolls Final Patient in Phase IIa Study of GNbAC1 in .. 
More tweets
Qtime:101
News from SeekingAlpha
02/12GENEURO SA ORD reports Q4 results 
2017GENEURO SA ORD reports Q3 results 
2017GeNeuro (GNRRF) Presents Review Of Phase llb Week-24 Results - Slideshow 
2017GENEURO SA ORD reports 1H results 
2017GENEURO SA ORD reports Q2 results 
Chart GENEURO
Duration : Period :
GeNeuro Technical Analysis Chart | GNRO | CH0308403085 | 4-Traders
Technical analysis trends GENEURO
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 11,5 €
Spread / Average Target 85%
EPS Revisions
Managers
NameTitle
Jesús Martin-Garcia Chairman & Chief Executive Officer
Miguel Payro Chief Financial Officer
Giacomo di Nepi Independent Director
Marc Bonneville Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GENEURO8.58%113
CELLTRION, INC.--.--%28 789
IQVIA HOLDINGS INC-1.18%20 413
LONZA GROUP-7.22%18 571
INCYTE CORPORATION-28.05%14 432
NEKTAR THERAPEUTICS41.51%13 751